Coronary Stenosis in a Patient Under Pazopanib Therapy: A Case Study

Tyrosine kinase inhibitors have transformed therapeutic approaches to cancer, marking a major advance in oncology. This article presents the clinical case of a 59-year-old moroccan patient with metastatic clear cell kidney cancer treated with pazopanib, who developed a cardiac vascular accident through coronary stenosis after 24 months of treatment with pazopanib. The main objective of this article is to illustrate the side effects of anti-angiogenic drugs and the crucial importance of monitoring these toxicities, particularly those of vascular origin, in order to prevent serious complications that could compromise the prognosis of a patient, regardless of the cancer disease itself. This case highlights the need for regular assessment of cardiovascular risk factors in patients receiving treatment with pazopanib, as well as increased vigilance for the appearance of signs or symptoms suggesting hematological or hepatic toxicities. Early and appropriate management of toxicities is essential to optimize the safety and effectiveness of renal cancer treatment with pazopanib, while preserving the patient's cardiovascular health.